CD33 and acute myeloid leukemia: To address this, Perriello et al., developed a dual CAR approach with a first-generation activating CD123.CAR and costimulatory CD33.CAR without activating domains to maintain anti-AML efficacy but circumventing anti-CD33-mediated toxicity [104].